Screener
Jazz Pharmaceuticals JAZZ Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of employee withholding taxes related to share-based awards | (103.6) | (67.2) |
| Repayments of long-term debt | (7.8) | (757.8) |
| Proceeds from employee equity incentive and purchase plans | 32.9 | 11.5 |
| Net cash used in financing activities | (78.5) | (813.5) |
| Effect of exchange rates on cash and cash equivalents | (0.4) | 1.7 |
| Net increase (decrease) in cash and cash equivalents | 452.4 | (551.0) |
| Cash and cash equivalents, at beginning of period | 1,391.9 | 2,412.9 |
| Cash and cash equivalents, at end of period | $1,844.3 | $1,861.9 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's financing cash flow?
- Jazz Pharmaceuticals (JAZZ) reported financing cash flow of -$78.5M in Q1 2026.
- How has Jazz Pharmaceuticals's financing cash flow changed year-over-year?
- Jazz Pharmaceuticals's financing cash flow increased by 90.4% year-over-year, from -$813.5M to -$78.5M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Jazz Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude